Instrument Inactif

Communiqués Regulus Therapeutics Inc Nasdaq

Actions

US75915K1016

Recherche biotechnologique et médicale

Communiqués

08/05/25	Regulus: Q1 Earnings Snapshot	AQ
08/05/25	Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates	PR
04/05/25	REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS	BU
30/04/25	Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG	PR
02/04/25	Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit	PR
27/03/25	Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PR
13/03/25	Regulus: Q4 Earnings Snapshot	AQ
13/03/25	Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates	PR
04/03/25	Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference	PR
04/02/25	Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
29/01/25	Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)	PR
26/11/24	Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences	PR
08/11/24	Regulus Therapeutics : Quarterly Report for Quarter Ending SEPTEMBER 30, 2024 (Form 10-Q)	PU
07/11/24	Regulus: Q3 Earnings Snapshot	AQ
07/11/24	Regulus Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Updates Form 8 K	PU
09/10/24	Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	AQ
08/10/24	Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PR
28/08/24	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences	PR
08/08/24	Regulus: Q2 Earnings Snapshot	AQ
08/08/24	Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates	PR
06/08/24	Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference	PR
09/07/24	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences	PR
24/06/24	Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PR
04/06/24	Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes	PR
17/05/24	APPENDIX A REGULUS THERAPEUTICS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 15, 2019 APPROVED BY THE STOCKHOLDERS: AUGUST 1, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 20, 2023 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2023 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2024 APPROVED BY THE STOCKHOLDERS: MAY 16, 2024 - Form 8-K	PU